WO1999041383A8 - Antigen library immunization - Google Patents
Antigen library immunizationInfo
- Publication number
- WO1999041383A8 WO1999041383A8 PCT/US1999/002944 US9902944W WO9941383A8 WO 1999041383 A8 WO1999041383 A8 WO 1999041383A8 US 9902944 W US9902944 W US 9902944W WO 9941383 A8 WO9941383 A8 WO 9941383A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigens
- antigen library
- library immunization
- obtaining
- methods
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12111—Hantavirus, e.g. Hantaan virus
- C12N2760/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19990932510 EP1054973A1 (en) | 1998-02-11 | 1999-02-10 | Antigen library immunization |
JP2000531564A JP2002507393A (en) | 1998-02-11 | 1999-02-10 | Antigen library immunization |
CA 2320958 CA2320958A1 (en) | 1998-02-11 | 1999-02-10 | Antigen library immunization |
AU32891/99A AU3289199A (en) | 1998-02-11 | 1999-02-10 | Antigen library immunization |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2176998A | 1998-02-11 | 1998-02-11 | |
US7429498P | 1998-02-11 | 1998-02-11 | |
US60/074,294 | 1998-02-11 | ||
US09/021,769 | 1998-02-11 | ||
US10550998P | 1998-10-23 | 1998-10-23 | |
US60/105,509 | 1998-10-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999041383A1 WO1999041383A1 (en) | 1999-08-19 |
WO1999041383A8 true WO1999041383A8 (en) | 1999-09-30 |
Family
ID=27361726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/002944 WO1999041383A1 (en) | 1998-02-11 | 1999-02-10 | Antigen library immunization |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1054973A1 (en) |
JP (1) | JP2002507393A (en) |
AU (1) | AU3289199A (en) |
CA (1) | CA2320958A1 (en) |
WO (1) | WO1999041383A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8959833B2 (en) | 2004-08-26 | 2015-02-24 | Monsanto Technology Llc | Methods of seed breeding using high throughput nondestructive seed sampling |
US8965101B2 (en) | 2007-05-31 | 2015-02-24 | Monsanto Technology Llc | Seed sorter |
US8997398B2 (en) | 2006-03-02 | 2015-04-07 | Monsanto Technology Llc | Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds |
US9383291B2 (en) | 2006-03-02 | 2016-07-05 | Monsanto Technology Llc | Automated contamination-free seed sampler and methods of sampling, testing and bulking seeds |
US9512382B2 (en) | 2009-10-16 | 2016-12-06 | Bunge Global Innovation, Llc | Oil degumming methods |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
WO1999023107A1 (en) | 1997-10-31 | 1999-05-14 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
CA2335269A1 (en) | 1998-06-17 | 1999-12-23 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
AU5347999A (en) | 1998-08-12 | 2000-03-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
EP1129184A1 (en) | 1998-11-10 | 2001-09-05 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes |
AUPP706098A0 (en) * | 1998-11-11 | 1998-12-03 | North Western Health Care Network | Biological compositions, components thereof and uses therefor |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
DK1072010T3 (en) | 1999-01-19 | 2010-06-21 | Maxygen Inc | Oligonucleotide-mediated nucleic acid recombination |
IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
AU7288600A (en) * | 1999-09-21 | 2001-04-24 | Artemis Pharmaceuticals Gmbh | Method for identifying mhc-restricted antigens |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
GB9928787D0 (en) * | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
US20010024796A1 (en) * | 1999-12-17 | 2001-09-27 | Selifonov Sergey A. | Methods for parallel detection of compositions having desired characteristics |
WO2001059071A2 (en) | 2000-02-09 | 2001-08-16 | Genvec, Inc. | Methods of preparing and using a viral vector library |
JP2004513878A (en) | 2000-06-23 | 2004-05-13 | マキシジェン, インコーポレイテッド | Novel costimulatory molecules |
US6858422B2 (en) | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
US7367155B2 (en) | 2000-12-20 | 2008-05-06 | Monsanto Technology Llc | Apparatus and methods for analyzing and improving agricultural products |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
US20030228327A1 (en) * | 2001-11-05 | 2003-12-11 | Lasher Alfred W. | DNA-based plasmid formulations and vaccines and prophylactics containing the same |
CN100534436C (en) * | 2001-11-21 | 2009-09-02 | 利兰·斯坦福青年大学托管委员会 | Polynucleotide therapy |
NZ535690A (en) | 2002-02-26 | 2009-04-30 | Maxygen Inc | Novel flavivirus antigens |
EP2278509B1 (en) | 2002-03-01 | 2014-11-19 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
JP4851687B2 (en) | 2002-03-09 | 2012-01-11 | マキシジェン, インコーポレイテッド | Crossover optimization for directed evolution |
DE60318032T2 (en) | 2002-04-04 | 2008-11-20 | Monsanto Technology Llc | AUTOMATED SYSTEM FOR RECEIVING, WEIGHING AND SORTING PARTICLE MATERIAL |
WO2003087128A2 (en) * | 2002-04-09 | 2003-10-23 | Rmf Dictagene S.A. | Secretory signal sequences and uses thereof |
BR0309391A (en) | 2002-04-19 | 2005-10-25 | Diversa Corp | Phospholipases, nucleic acids encoding them and methods for preparing and using them |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP1576151A4 (en) | 2002-08-06 | 2006-05-17 | Verdia Inc | Ap1 amine oxidase variants |
EP3508578A1 (en) | 2003-03-06 | 2019-07-10 | BASF Enzymes, LLC | Amylases, nucleic acids encoding them and methods for making and using them |
EP2853593B1 (en) | 2003-03-07 | 2017-10-04 | DSM IP Assets B.V. | Hydrolases, nucleic acids encoding them and mehods for making and using them |
DK2341136T3 (en) | 2003-04-04 | 2016-09-12 | Basf Enzymes Llc | Pectate lyases, nucleic acids encoding them, and methods of making and using them |
MXPA05011585A (en) | 2003-04-29 | 2006-05-25 | Pioneer Hi Bred Int | Novel glyphosate-n-acetyltransferase (gat) genes. |
WO2005003319A2 (en) | 2003-07-02 | 2005-01-13 | Diversa Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
WO2005021714A2 (en) | 2003-08-11 | 2005-03-10 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
WO2005031367A2 (en) | 2003-09-23 | 2005-04-07 | Monsanto Technology Llc | High throughput automated seed analysis system |
IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
CA2734716A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
BRPI0510939A (en) | 2004-06-16 | 2007-07-17 | Diversa Corp | compositions and methods for enzymatic chlorophyll discoloration |
EP1819212B1 (en) | 2004-08-26 | 2013-10-23 | Monsanto Technology, LLC | Automated testing of seeds |
EP2886658A1 (en) | 2005-03-10 | 2015-06-24 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
EP1861506B1 (en) | 2005-03-15 | 2015-04-15 | BP Corporation North America Inc. | Cellulases, nucleic acids encoding them and methods for making and using them |
US8715988B2 (en) | 2005-03-28 | 2014-05-06 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
WO2006125983A1 (en) * | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
WO2007092314A2 (en) | 2006-02-02 | 2007-08-16 | Verenium Corporation | Esterases and related nucleic acids and methods |
AU2006338208B2 (en) | 2006-02-10 | 2013-10-24 | Bp Corporation North America Inc. | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
EP2548955A1 (en) | 2006-02-14 | 2013-01-23 | Verenium Corporation | Xylanases, nucleic acids encoding them and methods for making and using them |
JP2009543541A (en) * | 2006-03-06 | 2009-12-10 | アムニクス, インコーポレイテッド | Non-structural recombinant polymers and uses thereof |
AU2007223888A1 (en) * | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
JP5441417B2 (en) | 2006-03-07 | 2014-03-12 | カーギル・インコーポレイテッド | Aldose, nucleic acid encoding it, and methods of generating and using it |
AU2007223086B2 (en) | 2006-03-07 | 2013-09-26 | Basf Enzymes Llc | Aldolases, nucleic acids encoding them and methods for making and using them |
RU2009102660A (en) | 2006-06-28 | 2010-08-10 | Монсанто Текнолоджи Ллс (Us) | INSTALLATION AND METHOD FOR SORTING SMALL ITEMS |
WO2009020459A2 (en) | 2006-08-04 | 2009-02-12 | Verenium Corporation | Glucanases, nucleic acids encoding them and methods for making and using them |
HUE025544T2 (en) | 2006-09-21 | 2016-02-29 | Basf Enzymes Llc | Phytases, nucleic acids encoding them and methods for making and using them |
EP2057274B1 (en) | 2006-09-21 | 2013-12-11 | DSM IP Assets B.V. | Phospholipases, nucleic acids encoding them and methods for making and using them |
PL2069490T5 (en) | 2006-12-21 | 2018-09-28 | Basf Enzymes Llc | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
CA2674721C (en) | 2007-01-30 | 2018-04-03 | Verenium Corporation | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
EP2000531A1 (en) * | 2007-06-06 | 2008-12-10 | Biomay AG | Antigen presenting cells |
WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
NZ601191A (en) | 2007-10-03 | 2014-01-31 | Verenium Corp | Xylanases, nucleic acids encoding them and methods for making and using them |
CN101965397B (en) | 2008-01-03 | 2016-09-28 | 巴斯夫酶有限责任公司 | Transferring enzyme and oxidoreductase, the nucleic acid encoding them and its methods for making and using same |
WO2009088753A1 (en) | 2008-01-03 | 2009-07-16 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
EP2297310A2 (en) | 2008-05-23 | 2011-03-23 | E. I. du Pont de Nemours and Company | Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2709481T3 (en) | 2008-09-26 | 2019-04-16 | Tocagen Inc | Recombinant vectors |
CN116925238A (en) | 2009-02-03 | 2023-10-24 | 阿穆尼克斯制药公司 | Extended recombinant polypeptides and compositions comprising the same |
BRPI1011160A8 (en) | 2009-05-21 | 2018-01-02 | Verenium Corp | PHYTASES, PROTEIN PREPARATION INCLUDING THEM, AND THEIR USES |
US8592649B2 (en) | 2009-08-20 | 2013-11-26 | Pioneer Hi Bred International Inc | Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
MX2012007681A (en) | 2009-12-31 | 2013-01-29 | Pioneer Hi Bred Int | Engineering plant resistance to diseases caused by pathogens. |
CA2805803A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity |
ES2935489T3 (en) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Factor VIII compositions and methods of preparation and use thereof |
LT2822577T (en) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
RU2705301C2 (en) | 2012-02-16 | 2019-11-06 | Влп Терапьютикс, Ллк | Virus-like particles composition |
RU2014148769A (en) | 2012-05-04 | 2016-06-27 | Е.И. Дюпон Де Немур Энд Компани | COMPOSITIONS AND METHODS INCLUDING SEQUENCES CHARACTERIZED BY MEGANUCLEASE ACTIVITY |
US20160040149A1 (en) | 2013-03-14 | 2016-02-11 | Pioneer Hi-Bred International Inc. | Compositions Having Dicamba Decarboxylase Activity and Methods of Use |
SG11201507455WA (en) * | 2013-03-14 | 2015-10-29 | Altravax Inc | Hepatitis b virus vaccines |
EP2970995A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
CA2901316A1 (en) | 2013-03-15 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Phi-4 polypeptides and methods for their use |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP3032942B1 (en) | 2013-08-16 | 2020-03-11 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EA031651B1 (en) | 2013-09-13 | 2019-02-28 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticidal proteins and methods for their use |
US10480007B2 (en) | 2014-02-07 | 2019-11-19 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants |
RU2747978C2 (en) | 2014-02-07 | 2021-05-18 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticidal proteins and their application methods |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
TWI720946B (en) | 2014-08-08 | 2021-03-11 | 美商Vlp醫療股份有限公司 | Virus like particle comprising modified envelope protein e3 |
CN106687590B (en) * | 2014-09-11 | 2021-08-03 | Vlp治疗公司 | Yellow fever virus-like particles |
RU2733898C2 (en) | 2014-10-16 | 2020-10-09 | Пайонир Хай-Бред Интернэшнл, Инк. | Insecticidal proteins and methods of using them |
EP3267796B1 (en) | 2015-03-11 | 2023-08-09 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of pip-72 and methods of use |
EP3294911B1 (en) * | 2015-05-11 | 2020-08-19 | Illumina, Inc. | Platform for discovery and analysis of therapeutic agents |
WO2016186986A1 (en) | 2015-05-19 | 2016-11-24 | Pioneer Hi Bred International Inc | Insecticidal proteins and methods for their use |
WO2017024084A1 (en) | 2015-08-03 | 2017-02-09 | University Of Washington | Immunogenic compositions, antigen screening methods, and methods of generating immune responses |
TWI741992B (en) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | Factor ix fusion proteins and methods of making and using same |
EP3943602A1 (en) | 2015-08-06 | 2022-01-26 | Pioneer Hi-Bred International, Inc. | Plant derived insecticidal proteins and methods for their use |
WO2017105987A1 (en) | 2015-12-18 | 2017-06-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
MX2018013249A (en) | 2016-05-04 | 2019-02-13 | Pioneer Hi Bred Int | Insecticidal proteins and methods for their use. |
MX2018015906A (en) | 2016-07-01 | 2019-04-04 | Pioneer Hi Bred Int | Insecticidal proteins from plants and methods for their use. |
BR112019008800A2 (en) | 2016-11-01 | 2019-07-16 | Pioneer Hi Bred Int | insecticidal polypeptide, insecticidal composition, recombinant polynucleotide, dna construct, plant cell or transgenic plant, method for inhibiting growth or exterminating an agricultural insect pest population, method for inhibiting growth or exterminating an insect pest, method for controlling lepidoptera and / or coleoptera insect infestation in a transgenic plant and provide insect resistance management and use of at least one insecticide polypeptide |
CN110088123B (en) | 2016-12-14 | 2023-10-20 | 先锋国际良种公司 | Insecticidal proteins and methods of use thereof |
CA3046226A1 (en) | 2016-12-22 | 2018-06-28 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
BR112019016394A2 (en) | 2017-02-08 | 2020-04-07 | Pioneer Hi Bred Int | DNA construct, molecular cell, breeding cell, transgenic plant or progeny thereof, composition and method for controlling an insect pest population |
WO2018208882A1 (en) | 2017-05-11 | 2018-11-15 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
EP4182466A2 (en) | 2020-07-14 | 2023-05-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691170A (en) * | 1989-04-18 | 1997-11-25 | Therion Biologics | Generation of hybrid genes and proteins by virus-mediated recombination |
US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
-
1999
- 1999-02-10 JP JP2000531564A patent/JP2002507393A/en not_active Withdrawn
- 1999-02-10 WO PCT/US1999/002944 patent/WO1999041383A1/en not_active Application Discontinuation
- 1999-02-10 CA CA 2320958 patent/CA2320958A1/en not_active Abandoned
- 1999-02-10 EP EP19990932510 patent/EP1054973A1/en not_active Withdrawn
- 1999-02-10 AU AU32891/99A patent/AU3289199A/en not_active Abandoned
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8959833B2 (en) | 2004-08-26 | 2015-02-24 | Monsanto Technology Llc | Methods of seed breeding using high throughput nondestructive seed sampling |
US8997398B2 (en) | 2006-03-02 | 2015-04-07 | Monsanto Technology Llc | Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds |
US9383291B2 (en) | 2006-03-02 | 2016-07-05 | Monsanto Technology Llc | Automated contamination-free seed sampler and methods of sampling, testing and bulking seeds |
US9551636B2 (en) | 2006-03-02 | 2017-01-24 | Monsanto Technology Llc | Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds |
US8965101B2 (en) | 2007-05-31 | 2015-02-24 | Monsanto Technology Llc | Seed sorter |
US9275265B2 (en) | 2007-05-31 | 2016-03-01 | Monsanto Technology Llc | Seed sorter |
US9512382B2 (en) | 2009-10-16 | 2016-12-06 | Bunge Global Innovation, Llc | Oil degumming methods |
Also Published As
Publication number | Publication date |
---|---|
WO1999041383A1 (en) | 1999-08-19 |
AU3289199A (en) | 1999-08-30 |
JP2002507393A (en) | 2002-03-12 |
CA2320958A1 (en) | 1999-08-19 |
EP1054973A1 (en) | 2000-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999041383A8 (en) | Antigen library immunization | |
WO2004032829A3 (en) | Immunostimulatory compositions and methods of stimulating an immune response | |
TW200510459A (en) | RG1 antibodies and uses thereof | |
WO2004112825A3 (en) | Combinations of tumor-associated antigens for the treatment of various types of cancers | |
WO2002006317A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
NZ605429A (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
WO2001014424A3 (en) | Human ctla-4 antibodies and their uses | |
GR3036229T3 (en) | Method for the production of antihuman antigen receptors and uses thereof | |
WO2004001381A3 (en) | Novel raag10 cell surface target and a family of antibodies recognizing that target | |
WO2007067681A3 (en) | Immunostimulatory compositions and methods | |
WO1999066879A3 (en) | Systemic immune activation method using nucleic acid-lipid complexes | |
MXPA04003291A (en) | Use of bispecific antibodies to regulate immune responses. | |
IL163902A0 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
EP1135415A4 (en) | Humanized antibodies to gamma-interferon | |
WO2003054007A3 (en) | Streptococcus antigens | |
MY125202A (en) | Vaccine | |
WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
IL201889A (en) | Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells | |
SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
WO2005120563A3 (en) | Induction of an immune response against streptococcus pneumoniae polysaccharides | |
HUP9903770A2 (en) | Method and composition for reconforming multi-epitopic antigens to initiate an immune response | |
WO2004043239A3 (en) | Antigen pipa and antibodies that bind thereto | |
WO2002078516A3 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
WO2005030793A3 (en) | Antibodies which bind human cxcr3 | |
WO2007084107A3 (en) | Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 33/99 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C12N 15/31, 15/36, 15/48, 15/51, C07K 19/00, 14/02, 14/16, 14/24, 14/035, 14/18, 14/31, 14/315, 14/28, 14/245, 14/35, 14/445, 14/435, C12N 15/10, 15/86" |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2320958 Country of ref document: CA Ref country code: JP Ref document number: 2000 531564 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2320958 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/007892 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 32891/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999932510 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999932510 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999932510 Country of ref document: EP |